AmBisome (amphotericin b): Reviews and patient testimonials
Medication indications
AmBisome
AmBisome is indicated in adults and children aged 1 month to 18 years old for:
• the treatment of severe systemic and/or deep mycoses
• the treatment of visceral leishmaniasis in immunocompetent patients including both adults and children
• the empirical treatment of presumed fungal infections in febrile neutropenic patients, where the fever has failed to respond to broad spectrum antibiotics and appropriate investigations have failed to define a bacterial or viral cause.
Infections successfully treated with AmBisome include: disseminated candidiasis, aspergillosis, mucormycosis, chronic mycetoma, cryptococcal meningitis and visceral leishmaniasis.
AmBisome should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests.
Molecule: amphotericin b
Patients' opinions on AmBisome
In brief
General satisfaction level: Be the first to evaluate
Treatment's effectiveness: Be the first to evaluate
Ease of use: Be the first to evaluate
Adherence to prescription: Be the first to evaluate
Detected side effects: Be the first to evaluate
Improvement in the quality of life: Be the first to evaluate
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Never
10 = Always
1 = Not at all important
10 = Extremely important
1 = Not at all satisfied
10 = Extremely satisfied
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.